Erectile dysfunction management after failed phosphodiesterase-5-inhibitor trial: a cost-effectiveness analysis
نویسندگان
چکیده
منابع مشابه
Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.
INTRODUCTION Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance.1 According to data from the Massachusetts Male Aging Study, up to 52% of men between the ages of 40 and 70 are affected by ED.2 Based on findings from the 2001–2002 National Health and Nutrition Examination Survey (NHANES), it is estimated that 18...
متن کاملPhosphodiesterase type 5 inhibitors for erectile dysfunction.
The cyclic nucleotide signalling pathway mediates the smooth-muscle relaxing effects of nitric oxide necessary for normal erectile function. Down-regulation of this pathway is central to the pathophysiology of many forms of erectile dysfunction (ED), which is often associated with other chronic diseases (e.g. hypertension, type 2 diabetes mellitus) and treatments (e.g. certain drugs, radical pr...
متن کاملVardenafil An oral selective phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction
Erectile dysfunction (ED) is defined as the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance.1 The Massachusetts Male Aging Study, a cross-sectional, community-based, random-sample survey, suggests that 10 million to 30 million men in the United States suffer from ED, with more than 900,000 estimated new cases annually.2 A higher prevalence of E...
متن کاملChronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
Oral phosphodiesterase type 5 (PDE5) inhibitors have provided non-invasive, effective, and well-tolerated treatments for patients with erectile dysfunction (ED). However, many patients with ED are unresponsive to 'on-demand' PDE5 inhibitors. In addition, the lack of spontaneity and naturalness of the on-demand regimen could be a reason for decreased compliance with PDE5 inhibitors. Recently, ta...
متن کاملLet’s rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy
As the radical prostatectomy (RP) for the patient diagnosed as localized prostate cancer has been increasing, erectile dysfunction (ED) associated with RP is increased and ED after RP is a significant risk factor to reduce the quality of life for the patient after RP. Therefore, the treatment concept called penile rehabilitation was introduced and phosphodiesterase type 5 inhibitor (PDE5I) is u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Translational Andrology and Urology
سال: 2019
ISSN: 2223-4683,2223-4691
DOI: 10.21037/tau.2019.03.10